益生菌
疾病
医学
乳酸菌
肝病
代谢综合征
生物
肥胖
食品科学
胃肠病学
内科学
细菌
遗传学
发酵
作者
Minwen Gu,Qing Hong,Jie Cui,Wenhui Li,Jian Zhang,Ye Sun,Jinchi Jiang,Yonghong Hu
标识
DOI:10.1080/10408398.2025.2504162
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) involves fat buildup in the liver and is connected to a disruption in gut microbiota and a reduction in beneficial microbiota. Lactobacillus is an important probiotic that can grow in anaerobic or low-oxygen environment and is widely used in food industry and health fields. In recent years, the improvement of MASLD by Lactobacillus has been extensively studied. However, the detailed mechanisms by which different species of Lactobacillus improve MASLD have not been summarized. In this review, we present the potential of Lactobacillus as a non-drug approach to mitigate MASLD. We will discuss the preclinical and clinical research backing this method and the ways these probiotics improve MASLD. This review mainly presents the different species of Lactobacillus that improve MASLD, and various mechanisms by which Lactobacillus strains alleviate MASLD, including improving intestinal permeability and inflammation, reducing oxidative stress, and restoring of gut metabolites. Future research into mechanisms and larger clinical trials will help confirm the effectiveness of using Lactobacillus and related genera in the treatment of MASLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI